Page 38 - Includes Docubay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Year 2024, started with contrarian buy call by note by a large foreign brokerage and the impact on the IT stocks is visible as they stand out in green territory. One of the basic principles of figuring out whether the stock prices have bottomed out or have topped out is how they react to the negative and positive news. It is after a long period of time that IT stocks have reacted to positive news. When news is bad and most are skeptical it is time to look at businesses which have a track record of delivering and have strong balance sheets but due to some reason out of favour. Stock Reports Plu...

After a minor corrective phase, while the mid and small caps are once again in party mode, large caps have been lagging in a relative manner. But investing in not about a quarter or week, it is much more than them. If one looks at the long term, large caps are able to outperform and create wealth in a more sustainable manner. So probably a short phase of underperformance due to the fact that everyone is chasing short term performance due to recency bias might be an opportunity to look at some stocks with a long term perspective.

Even when nifty and Sensex had been correcting, midcap stocks have been continuing with their party. Today when nifty is trading in green, the gain in midcap indices are higher as they continue to outperform. This is happening as the “risk on trade” continues with all the positive news across the globe and is clearly reflected in the overall markets breadth which is extremely positive. Over the next few weeks, if there is a resumption of positive FII flow than we might see these stocks getting pushed. ET screener powered by Refinitiv’s Stock Report Plus lists down quality st...

The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might appear to be a sudden up move, if one looks at what has happened in the pharma sector in the last eight years, there is a good chance that right from valuation readjustments to changing business model might play a role bringing the large pharma companies back into limelight. Infact some of these stocks have quietly inched upward in the last few months. It might be too early to call, but if a re-rating plays out in this space, it might surprise many in terms ...

As an investor there are certain things which are under your control when making a decision to buy stocks. One of them is that before buying the stock, do some basic home work like what is the business of the company and how that company is placed in the industry and what are some of its basic key ratios. This work will not only save not only money but also lots of anxiety when there is a correction in markets. The problem with not even looking at basics is that when the market corrects as it has been doing for the last three sessions, decisions to exit are made in hurry, just based on price a...